OSTX · Company research
OS Therapies Incorporated (OSTX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
16records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| OS Therapies Incorporated (OSTX) Stock Price, News, Quote & History - Yahoo Finance | OS Therapies Incorporated (OSTX) Stock Price, News, Quote & History Yahoo Finance | View source ↗ | Yahoo Finance | Oct 12, 2026 | neutral | 0 | 0.6 |
| OS (OSTX) Retreats -1.85%, Breaching $1.51 Support Line 2026-10-09 - Bollinger Expansion - https://www.dars.gov.et/ | OS (OSTX) Retreats -1.85%, Breaching $1.51 Support Line 2026-10-09 - Bollinger Expansion https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Oct 9, 2026 | neutral | 0 | 0.6 |
| OS Therapies Incorporated (OSTX) Stock Price, News, Quote & History - Yahoo! Finance Canada | OS Therapies Incorporated (OSTX) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| A dog cancer treatment could launch in the U.S. in 2027, OS Therapies hopes - Stock Titan | A dog cancer treatment could launch in the U.S. in 2027, OS Therapies hopes Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| OSTX Stock Holds Tight Range As Traders Probe Weak Financials - StocksToTrade | OSTX Stock Holds Tight Range As Traders Probe Weak Financials StocksToTrade | View source ↗ | StocksToTrade | Oct 6, 2026 | neutral | 0 | 0.6 |
| 72.7% of treated patients survived three years, versus 45.8% in historical comparisons. - Stock Titan | 72.7% of treated patients survived three years, versus 45.8% in historical comparisons. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| Os Therapies Incorporated (OSTX-A) Stock Price and News - The Globe and Mail | Os Therapies Incorporated (OSTX-A) Stock Price and News The Globe and Mail | View source ↗ | The Globe and Mail | Oct 1, 2026 | neutral | 0 | 0.6 |
| The FDA has approved 29 U.K.-led cancer drugs since 2021. Now a U.K. regulator will lead OS Therapies’ review. - Stock Titan | The FDA has approved 29 U.K.-led cancer drugs since 2021. Now a U.K. regulator will lead OS Therapies’ review. Stock Titan | View source ↗ | Stock Titan | Sep 21, 2026 | neutral | 0 | 0.6 |
| Analysts’ Top NA Picks: BioAge Labs, Inc. (BIOA), OS Therapies Incorporated (OSTX) - The Globe and Mail | Analysts’ Top NA Picks: BioAge Labs, Inc. (BIOA), OS Therapies Incorporated (OSTX) The Globe and Mail | View source ↗ | The Globe and Mail | Sep 10, 2026 | neutral | 0 | 0.6 |
| OS Therapies Launches $75 Million ATM Program Under Sales Agreement With Jefferies - TradingView | OS Therapies Launches $75 Million ATM Program Under Sales Agreement With Jefferies TradingView | View source ↗ | TradingView | Aug 21, 2026 | neutral | 0 | 0.6 |
| Why is OS Therapies stock surging today? - Investing.com | Why is OS Therapies stock surging today? Investing.com | View source ↗ | Investing.com | Jul 9, 2026 | neutral | 0 | 0.6 |
| OS Dives - Baystreet.ca | OS Dives Baystreet.ca | View source ↗ | Baystreet.ca | Jun 30, 2026 | neutral | 0 | 0.6 |
| OS Therapies Incorporated(NYSEAM:OSTX) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com | OS Therapies Incorporated(NYSEAM:OSTX) dropped from Russell Microcap Growth Benchmark Index marketscreener.com | View source ↗ | marketscreener.com | Jun 29, 2026 | neutral | 0 | 0.6 |
| Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX - Business Wire | Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX Business Wire | View source ↗ | Business Wire | Apr 10, 2026 | neutral | 0 | 0.6 |
| OSTX Analyst Rating Maintained at 'Buy' with $20 Price Target | OSTX Stock News - GuruFocus | OSTX Analyst Rating Maintained at 'Buy' with $20 Price Target | OSTX Stock News GuruFocus | View source ↗ | GuruFocus | Apr 8, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Dec 18, 2023 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.